Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future
Figure 1
Retrospective analysis of outcome of newly diagnosed patients aged 65–70 years. Progression-free and overall survival according to the treatment groups such as conventional chemotherapy, conventional chemotherapy + novel drugs, conventional chemotherapy + ASCT, and novel drugs + ASCT is shown. Reproduced from [40] with permission from Karger.
